FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022237719> ?p ?o ?g. }

• W2022237719 endingPage "911" @default.
• W2022237719 startingPage "905" @default.
• W2022237719 abstract "TRITON-TIMI 38 showed that in patients with acute coronary syndrome undergoing percutaneous coronary intervention prasugrel decreased ischemic events compared to standard clopidogrel, but with more bleeding. The United States Food and Drug Administration and the European Medicines Agency approved prasugrel but provided contraindications in patients with previous stroke or transient ischemic attack and recommended limited use or reduced dose in patients ≥75 years old and weighing <60 kg. This defined 3 clinically relevant groups of patients for use of prasugrel at the studied dose regimen: group I (core clinical cohort), group II (noncore cohort), and group III (contraindicated). We assessed clinical outcomes of patients within these cohorts in the TRITON-TIMI 38 trial. Survival analysis methods were used to compare outcomes by treatment assignment (prasugrel vs clopidogrel) and by cohort (groups I and II or III). Patients in group I (n = 10,804, 79%) treated with prasugrel had a clinically significant and robust decrease in the primary end point of cardiovascular death, myocardial infarction, or stroke (8.3 vs 11.0%, hazard ratio [HR] 0.74, 95% confidence interval 0.66 to 0.84, p <0.0001), whereas patients in group II (n = 2149, 16%) had limited efficacy (15.3% vs 16.3%, HR 0.94, 0.76 to 1.18, p = 0.61, p for interaction = 0.07). For Thrombolysis In Myocardial Infarction major bleeding not related to coronary artery bypass grafting, there were tendencies to higher rates with prasugrel in group I (1.9% vs 1.5%, HR 1.24, 0.91 to 1.69, p = 0.17) and group II (4.1% vs 3.4%, HR 1.23, 0.77 to 1.97, p = 0.40); however, the absolute difference was greater for group II. The net clinical outcome (all-cause death/myocardial infarction/stroke/Thrombolysis In Myocardial Infarction major bleeding) in group I patients was highly favorable (10.2% vs 12.5%, HR 0.80, 0.71 to 0.89, p <0.0001) and neutral in group II (19.5% vs 19.7%, HR 0.98, 0.81 to 1.20, p for interaction = 0.07). Patients in group III (n = 518, 4%) did poorly with regard to efficacy and safety. In TRITON-TIMI 38 patients without previous stroke, <75 years old, and weighing >60 kg had substantial decreases in ischemic events with prasugrel compared to clopidogrel. Although relative bleeding excess exists in this population, absolute rates and differences in bleeding were attenuated. In conclusion, these data indicate that use of prasugrel in a core clinical cohort that has been defined by regulatory action will maximize the benefit of prasugrel and limit the risk of adverse outcomes. TRITON-TIMI 38 showed that in patients with acute coronary syndrome undergoing percutaneous coronary intervention prasugrel decreased ischemic events compared to standard clopidogrel, but with more bleeding. The United States Food and Drug Administration and the European Medicines Agency approved prasugrel but provided contraindications in patients with previous stroke or transient ischemic attack and recommended limited use or reduced dose in patients ≥75 years old and weighing <60 kg. This defined 3 clinically relevant groups of patients for use of prasugrel at the studied dose regimen: group I (core clinical cohort), group II (noncore cohort), and group III (contraindicated). We assessed clinical outcomes of patients within these cohorts in the TRITON-TIMI 38 trial. Survival analysis methods were used to compare outcomes by treatment assignment (prasugrel vs clopidogrel) and by cohort (groups I and II or III). Patients in group I (n = 10,804, 79%) treated with prasugrel had a clinically significant and robust decrease in the primary end point of cardiovascular death, myocardial infarction, or stroke (8.3 vs 11.0%, hazard ratio [HR] 0.74, 95% confidence interval 0.66 to 0.84, p <0.0001), whereas patients in group II (n = 2149, 16%) had limited efficacy (15.3% vs 16.3%, HR 0.94, 0.76 to 1.18, p = 0.61, p for interaction = 0.07). For Thrombolysis In Myocardial Infarction major bleeding not related to coronary artery bypass grafting, there were tendencies to higher rates with prasugrel in group I (1.9% vs 1.5%, HR 1.24, 0.91 to 1.69, p = 0.17) and group II (4.1% vs 3.4%, HR 1.23, 0.77 to 1.97, p = 0.40); however, the absolute difference was greater for group II. The net clinical outcome (all-cause death/myocardial infarction/stroke/Thrombolysis In Myocardial Infarction major bleeding) in group I patients was highly favorable (10.2% vs 12.5%, HR 0.80, 0.71 to 0.89, p <0.0001) and neutral in group II (19.5% vs 19.7%, HR 0.98, 0.81 to 1.20, p for interaction = 0.07). Patients in group III (n = 518, 4%) did poorly with regard to efficacy and safety. In TRITON-TIMI 38 patients without previous stroke, <75 years old, and weighing >60 kg had substantial decreases in ischemic events with prasugrel compared to clopidogrel. Although relative bleeding excess exists in this population, absolute rates and differences in bleeding were attenuated. In conclusion, these data indicate that use of prasugrel in a core clinical cohort that has been defined by regulatory action will maximize the benefit of prasugrel and limit the risk of adverse outcomes." @default.
• W2022237719 created "2016-06-24" @default.
• W2022237719 creator A5019612250 @default.
• W2022237719 creator A5020677154 @default.
• W2022237719 creator A5022267024 @default.
• W2022237719 creator A5041316502 @default.
• W2022237719 creator A5055382903 @default.
• W2022237719 creator A5071615009 @default.
• W2022237719 creator A5085897222 @default.
• W2022237719 date "2011-10-01" @default.
• W2022237719 modified "2023-09-27" @default.
• W2022237719 title "Efficacy and Safety of Intensive Antiplatelet Therapy With Prasugrel from TRITON-TIMI 38 in a Core Clinical Cohort Defined by Worldwide Regulatory Agencies" @default.
• W2022237719 cites W1433020779 @default.
• W2022237719 cites W1964382651 @default.
• W2022237719 cites W1985059672 @default.
• W2022237719 cites W1991655882 @default.
• W2022237719 cites W2005726649 @default.
• W2022237719 cites W2034514998 @default.
• W2022237719 cites W2060063218 @default.
• W2022237719 cites W2086599873 @default.
• W2022237719 cites W2096069261 @default.
• W2022237719 cites W2111109999 @default.
• W2022237719 cites W2146453185 @default.
• W2022237719 cites W2146743728 @default.
• W2022237719 cites W2152823642 @default.
• W2022237719 cites W2169387542 @default.
• W2022237719 cites W2170125927 @default.
• W2022237719 cites W2397867274 @default.
• W2022237719 cites W4251889856 @default.
• W2022237719 doi "https://doi.org/10.1016/j.amjcard.2011.05.020" @default.
• W2022237719 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21816379" @default.
• W2022237719 hasPublicationYear "2011" @default.
• W2022237719 type Work @default.
• W2022237719 sameAs 2022237719 @default.
• W2022237719 citedByCount "60" @default.
• W2022237719 countsByYear W20222377192012 @default.
• W2022237719 countsByYear W20222377192013 @default.
• W2022237719 countsByYear W20222377192014 @default.
• W2022237719 countsByYear W20222377192015 @default.
• W2022237719 countsByYear W20222377192016 @default.
• W2022237719 countsByYear W20222377192017 @default.
• W2022237719 countsByYear W20222377192018 @default.
• W2022237719 countsByYear W20222377192019 @default.
• W2022237719 countsByYear W20222377192020 @default.
• W2022237719 countsByYear W20222377192021 @default.
• W2022237719 countsByYear W20222377192022 @default.
• W2022237719 crossrefType "journal-article" @default.
• W2022237719 hasAuthorship W2022237719A5019612250 @default.
• W2022237719 hasAuthorship W2022237719A5020677154 @default.
• W2022237719 hasAuthorship W2022237719A5022267024 @default.
• W2022237719 hasAuthorship W2022237719A5041316502 @default.
• W2022237719 hasAuthorship W2022237719A5055382903 @default.
• W2022237719 hasAuthorship W2022237719A5071615009 @default.
• W2022237719 hasAuthorship W2022237719A5085897222 @default.
• W2022237719 hasConcept C126322002 @default.
• W2022237719 hasConcept C164705383 @default.
• W2022237719 hasConcept C207103383 @default.
• W2022237719 hasConcept C2777028646 @default.
• W2022237719 hasConcept C2777849778 @default.
• W2022237719 hasConcept C2777995511 @default.
• W2022237719 hasConcept C2779837110 @default.
• W2022237719 hasConcept C2780400711 @default.
• W2022237719 hasConcept C44249647 @default.
• W2022237719 hasConcept C500558357 @default.
• W2022237719 hasConcept C71924100 @default.
• W2022237719 hasConcept C72563966 @default.
• W2022237719 hasConceptScore W2022237719C126322002 @default.
• W2022237719 hasConceptScore W2022237719C164705383 @default.
• W2022237719 hasConceptScore W2022237719C207103383 @default.
• W2022237719 hasConceptScore W2022237719C2777028646 @default.
• W2022237719 hasConceptScore W2022237719C2777849778 @default.
• W2022237719 hasConceptScore W2022237719C2777995511 @default.
• W2022237719 hasConceptScore W2022237719C2779837110 @default.
• W2022237719 hasConceptScore W2022237719C2780400711 @default.
• W2022237719 hasConceptScore W2022237719C44249647 @default.
• W2022237719 hasConceptScore W2022237719C500558357 @default.
• W2022237719 hasConceptScore W2022237719C71924100 @default.
• W2022237719 hasConceptScore W2022237719C72563966 @default.
• W2022237719 hasIssue "7" @default.
• W2022237719 hasLocation W20222377191 @default.
• W2022237719 hasLocation W20222377192 @default.
• W2022237719 hasOpenAccess W2022237719 @default.
• W2022237719 hasPrimaryLocation W20222377191 @default.
• W2022237719 hasRelatedWork W1966014541 @default.
• W2022237719 hasRelatedWork W1987984427 @default.
• W2022237719 hasRelatedWork W2004017808 @default.
• W2022237719 hasRelatedWork W2005726649 @default.
• W2022237719 hasRelatedWork W2120872726 @default.
• W2022237719 hasRelatedWork W2126722803 @default.
• W2022237719 hasRelatedWork W2127687375 @default.
• W2022237719 hasRelatedWork W2461821857 @default.
• W2022237719 hasRelatedWork W2799694914 @default.
• W2022237719 hasRelatedWork W2182195484 @default.
• W2022237719 hasVolume "108" @default.
• W2022237719 isParatext "false" @default.
• W2022237719 isRetracted "false" @default.
• W2022237719 magId "2022237719" @default.
• W2022237719 workType "article" @default.